JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Search

Boston Scientific Corp.

Fechado

SetorSaúde

55.97 -1.62

Visão Geral

Variação de preço das ações

24h

Atual

Mín

55.87

Máximo

56.99

Indicadores-chave

By Trading Economics

Rendimento

-83M

672M

Vendas

-83M

5.2B

P/E

Médio do Setor

25.084

67.147

EPS

0.8

Margem de lucro

12.713

Funcionários

59,000

EBITDA

116M

1.1B

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+56.76% upside

Dividendos

By Dow Jones

Próximos Ganhos

29 de jul. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-1.5B

89B

Abertura anterior

57.59

Fecho anterior

55.97

Sentimento de Notícias

By Acuity

51%

49%

281 / 347 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Boston Scientific Corp. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

22 de abr. de 2026, 11:22 UTC

Ganhos

Boston Scientific 1Q Net Grows Sharply, Company Cuts 2026 Adjusted EPS View

4 de fev. de 2026, 16:14 UTC

Ganhos
Grandes Movimentos do Mercado

Boston Scientific Plunges on Disappointing 1Q Outlook Despite 4Q Earnings Beat

4 de fev. de 2026, 12:13 UTC

Ganhos

Boston Scientific Sees More Growth after Earnings, Sales Rise

22 de abr. de 2026, 11:07 UTC

Ganhos

Boston Scientific 1Q Net Grows Sharply, Company Cuts 2026 Adj EPS View

22 de abr. de 2026, 10:32 UTC

Ganhos

Boston Scientific Now Sees 2026 Reported Sales Up 7%-8.5%, Organic Sales Up 6.5%-8% >BSX

22 de abr. de 2026, 10:31 UTC

Ganhos

Boston Scientific Sees 2Q Reported Sales Up 5.5%-7.5%, Organic Sales Up 5%-7% >BSX

22 de abr. de 2026, 10:30 UTC

Ganhos

Boston Scientific 1Q Organic Sales Up 9.4% >BSX

22 de abr. de 2026, 10:30 UTC

Ganhos

Boston Scientific 1Q Adj EPS 80c >BSX

22 de abr. de 2026, 10:30 UTC

Ganhos

Boston Scientific 1Q EPS 90c >BSX

22 de abr. de 2026, 10:30 UTC

Ganhos

Boston Scientific 1Q Sales $5.2B >BSX

22 de abr. de 2026, 10:30 UTC

Ganhos

Boston Scientific Sees 2Q Adj EPS 82c-Adj EPS 84c >BSX

22 de abr. de 2026, 10:30 UTC

Ganhos

Boston Scientific Sees FY Adj EPS $3.34-Adj EPS $3.41 >BSX

30 de mar. de 2026, 15:34 UTC

Conversa de Mercado

Boston Scientific Faces Some Slowing Growth Trends -- Market Talk

4 de fev. de 2026, 21:41 UTC

Ganhos

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4 de fev. de 2026, 19:38 UTC

Ganhos

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4 de fev. de 2026, 17:32 UTC

Ganhos

These Stocks Are Today's Movers: AMD, AbbVie, Eli Lilly, Boston Scientific, MP Materials, Super Micro, Silicon Labs, Uber, and More -- Barrons.com

4 de fev. de 2026, 15:30 UTC

Ganhos

Boston Scientific Earnings Beat Estimates. It's the Worst Stock in the S&P 500 Today. -- Barrons.com

4 de fev. de 2026, 15:29 UTC

Ganhos

These Stocks Are Today's Movers: AMD, Eli Lilly, AbbVie, Uber, Super Micro, Enphase, Boston Scientific, and More -- Barrons.com

4 de fev. de 2026, 14:06 UTC

Ganhos

Boston Scientific Profit, Sales Rise but Issues Soft Guidance -- Update

4 de fev. de 2026, 13:58 UTC

Ganhos

Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply. -- Barrons.com

4 de fev. de 2026, 13:12 UTC

Ganhos

Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply. -- Barrons.com

4 de fev. de 2026, 11:32 UTC

Ganhos

Boston Scientific Sees 2026 Sales Up 10.5%-11.5%, Organic Sales Up 10%-11% >BSX

4 de fev. de 2026, 11:31 UTC

Ganhos

Boston Scientific Sees 1Q Sales Up 10.5%-12%, Organic Sales Up 8.5%-10% >BSX

4 de fev. de 2026, 11:30 UTC

Ganhos

Boston Scientific 4Q Organic Sales Up 12.7% >BSX

4 de fev. de 2026, 11:30 UTC

Ganhos

Boston Scientific Sees 2026 Adj EPS $3.43-Adj EPS $3.49 >BSX

4 de fev. de 2026, 11:30 UTC

Ganhos

Boston Scientific Sees 1Q Adj EPS 78c-Adj EPS 80c >BSX

4 de fev. de 2026, 11:30 UTC

Ganhos

Boston Scientific 4Q Adj EPS 80c >BSX

4 de fev. de 2026, 11:30 UTC

Ganhos

Boston Scientific 4Q Sales $5.29B >BSX

4 de fev. de 2026, 11:30 UTC

Ganhos

Boston Scientific 4Q EPS 45c >BSX

24 de jan. de 2026, 06:18 UTC

Aquisições, Fusões, Aquisições de Empresas

Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. -- Barrons.com

Comparação entre Pares

Variação de preço

Boston Scientific Corp. Previsão

Preço-alvo

By TipRanks

56.76% parte superior

Previsão para 12 meses

Média 89.12 USD  56.76%

Máximo 118 USD

Mínimo 71 USD

Com base em 27 analistas de Wall Street que oferecem metas de preço de 12 meses para Boston Scientific Corp. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

27 ratings

26

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

102.95 / 104.93Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

No Evidence

Sentimento

By Acuity

281 / 347 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat